Nipro Of Japan To Begin Marketing Human iPS Cells To Drug Makers
This article was originally published in PharmAsia News
Japan's Nipro says it plans to launch soon the nation's first sale of cultivated human stem cells to drug makers and research institutes. Nipro said sales should begin in June of cardiac muscle cells developed from human induced pluripotent stem cells. Similar cells from iPS cells in monkeys already are available on the market, but Nipro expects the human samples to enable assessments of drug side effects more readily, improving the speed and efficacy of clinical tests. The cells to be marketed as kits were produced by ReproCell, a Japanese biotech venture. (Click here for more - a subscription may be required
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.